Loading
Latest filing published 18 Jun 2025 for Zentalis Pharmaceuticals, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Enoch Kariuki (board member) discloses dealings in Zentalis Pharmaceuticals, Inc. to SEC (Form 4). The record holds 4 filings, for trades running from 8 June 2022 to 17 June 2025.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The newest entry dates from 18 June 2025: a share grant, in Zentalis Pharmaceuticals, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations